The stock of Delcath Systems, Inc. (NASDAQ:DCTH) is a huge mover today! The stock decreased 28.41% or $0.98 on September 30, hitting $2.47. About 425,309 shares traded hands or 3049.50% up from the average. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 20.14% since February 26, 2016 and is downtrending. It has underperformed by 30.56% the S&P500.
The move comes after 7 months negative chart setup for the $3.62M company. It was reported on Oct, 1 by Barchart.com. We have $2.22 PT which if reached, will make NASDAQ:DCTH worth $362,000 less.
Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.
According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.30, from 1.43 in 2016Q1. The ratio is negative, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
One Trading L P accumulated 0% or 5,123 shares. Royal National Bank Of Canada accumulated 2,563 shares or 0% of the stock. Renaissance Technologies Limited Co holds 0% or 754,998 shares in its portfolio. Vanguard has 0% invested in the company for 77,988 shares. Goldman Sachs Grp Incorporated holds 0% or 15,211 shares in its portfolio. Private Advisor Gp Limited holds 206,670 shares or 0% of its portfolio. Geode Capital Management Ltd Llc holds 39,792 shares or 0% of its portfolio. The California-based Wells Fargo Mn has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Deutsche Bank & Trust Ag, a Germany-based fund reported 5 shares. Blackrock Fund Advsrs last reported 4,024 shares in the company. Citadel Advsr Ltd Liability holds 0% or 157,333 shares in its portfolio. Ladenburg Thalmann Service reported 1,456 shares or 0% of all its holdings. Barclays Public Ltd Com has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Kcg owns 12,403 shares or 0% of their US portfolio. The California-based Blackrock Institutional Na has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH).
More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Prnewswire.com which released: “Delcath Announces Proposed Public Offering of Common Stock and Warrants” on September 29, 2016, also Seekingalpha.com with their article: “Delcath prices stock offering at $3; shares off 21%” published on September 30, 2016, Marketwatch.com published: “Delcath Systems Inc.” on December 22, 2009. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: Benzinga.com and their article: “Mid-Morning Market Update: Markets Open Higher; McCormick Profit Tops Estimates” published on September 30, 2016 as well as Prnewswire.com‘s news article titled: “Delcath Sponsors Ocular Melanoma Foundation Patient Retreat” with publication date: September 19, 2016.
DCTH Company Profile
Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.